icad inc (ICAD) - Cash Flow Conversion Efficiency

Latest as of March 2025: 0.002x

Based on the latest financial reports, icad inc (ICAD) has a cash flow conversion efficiency ratio of 0.002x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($60.00K) by net assets ($30.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see icad inc market capitalisation for the company's overall valuation and market capitalisation.

icad inc - Cash Flow Conversion Efficiency Trend (1988–2024)

This chart illustrates how icad inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

icad inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of icad inc ranked by their cash flow conversion efficiency. Explore icad inc (ICAD) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Seer Inc
NASDAQ:SEER
-0.042x
PT Buana Artha Anugerah Tbk
JK:STAR
-0.003x
Protech Mitra Perkasa Tbk PT
JK:OASA
-0.061x
Bogota Financial Corp
NASDAQ:BSBK
0.002x
Yi Jinn Industrial Co Ltd
TW:1457
0.020x
Yoosung T&S Co. Ltd
KQ:024800
0.004x
Zeotech Ltd
AU:ZEO
-0.080x
Kalray SA
PA:ALKAL
0.230x

Annual Cash Flow Conversion Efficiency for icad inc (1988–2024)

The table below shows the annual cash flow conversion efficiency of icad inc from 1988 to 2024. View today's stock price for icad inc for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $28.68 Million $-3.94 Million -0.138x +7.41%
2023-12-31 $33.42 Million $-4.96 Million -0.149x +59.46%
2022-12-31 $34.90 Million $-12.79 Million -0.366x -81.18%
2021-12-31 $46.52 Million $-9.41 Million -0.202x +11.62%
2020-12-31 $30.52 Million $-6.99 Million -0.229x +83.67%
2019-12-31 $5.07 Million $-7.11 Million -1.401x -149.93%
2018-12-31 $6.90 Million $-3.87 Million -0.561x -9.11%
2017-12-31 $14.28 Million $-7.34 Million -0.514x -134.90%
2016-12-31 $25.04 Million $-5.48 Million -0.219x -277.07%
2015-12-31 $32.75 Million $-1.90 Million -0.058x -213.69%
2014-12-31 $62.78 Million $3.20 Million 0.051x +176.62%
2013-12-31 $21.38 Million $-1.42 Million -0.067x +56.16%
2012-12-31 $27.66 Million $-4.20 Million -0.152x +45.98%
2011-12-31 $36.05 Million $-10.14 Million -0.281x -10032.78%
2010-12-31 $73.21 Million $207.33K 0.003x -94.55%
2009-12-31 $66.31 Million $3.44 Million 0.052x -64.80%
2008-12-31 $66.29 Million $9.78 Million 0.147x +1153.97%
2007-12-31 $48.85 Million $574.57K 0.012x +112.79%
2006-12-31 $47.97 Million $-4.41 Million -0.092x -273.93%
2005-12-31 $52.73 Million $-1.30 Million -0.025x +28.16%
2004-12-31 $56.97 Million $-1.95 Million -0.034x +64.87%
2003-12-31 $47.90 Million $-4.67 Million -0.097x +7.33%
2002-12-31 $21.46 Million $-2.26 Million -0.105x +84.43%
2001-12-31 $2.04 Million $-1.38 Million -0.675x -241.10%
2000-12-31 $2.90 Million $-574.33K -0.198x +40.63%
1999-12-31 $3.00 Million $-1.00 Million -0.333x +63.49%
1998-12-31 $2.30 Million $-2.10 Million -0.913x -172.19%
1997-12-31 $3.40 Million $4.30 Million 1.265x +618.53%
1996-12-31 $4.10 Million $-1.00 Million -0.244x -72.76%
1995-12-31 $8.50 Million $-1.20 Million -0.141x -374.29%
1994-12-31 $13.60 Million $700.00K 0.051x -85.38%
1993-12-31 $12.50 Million $4.40 Million 0.352x +396.71%
1992-12-31 $12.70 Million $900.00K 0.071x +216.22%
1991-12-31 $8.20 Million $-500.00K -0.061x +83.36%
1990-12-31 $13.10 Million $-4.80 Million -0.366x -131.81%
1988-12-31 $7.90 Million $9.10 Million 1.152x --

About icad inc

NASDAQ:ICAD USA Medical Devices
Market Cap
$106.31 Million
Market Cap Rank
#19061 Global
#4402 in USA
Share Price
$3.87
Change (1 day)
+0.00%
52-Week Range
$3.87 - $3.87
All Time High
$21.22
About

iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurat… Read more